Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D Study a

Journal of Infectious Diseases

Volumn 207, Issue 9, 2013, Pages 1359-1369

  Ryom, Lene ^a   Mocroft, Amanda ^c   Kirk, Ole ^a,b   Worm, Signe W ^a   Kamara, David A ^c   Reiss, Peter ^d   Ross, Michael ^e   Fux, Christoph A ^f   Morlat, Philippe ^g   Moranne, Olivier ^h   Smith, Colette ^c   Lundgren, Jens D ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f Clinic for Infectious Diseases and Hospital Hygiene   (Switzerland)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

ART; atazanavir; chronic kidney disease; eGFR; HIV; lopinavir; nephrotoxicity; tenofovir

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; INDINAVIR; LOPINAVIR; NUCLEOSIDE; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; WITHHOLDING TREATMENT;

EID: 84875971855     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit043     Document Type: Article

References (50)

1. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24:1667-78.
2. Flandre P, Pugliese P, Cuzin L, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clinical Journal of the American Society of Nephrology:CJASN 2011; 6:1700-7.
3. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26:867-75.
4. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. The Journal of Infectious Diseases 2011; 204:1191-201.
5. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA. Baseline kidney function as predictor of mortality and kidney disease progression in HIV-Positive patients. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation 2012; 60:539-47.
6. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. The New England Journal of Medicine 2003; 349:1993-2003.
7. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of Internal Medicine 2003; 139:137-47.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
9. Mosteller RD. Simplified calculation of body-surface area. The New England Journal of Medicine 1987; 317:1098.
10. Vrouenraets SM, Fux CA, Wit FW, et al. A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function. Clinical Nephrology 2012; 77:311-20.
11. Boehringer Ingelheim Pharmaceuticals I. Highlights of prescribing information. http://bidocs.boehringer-ingelheim.com/BIWebAccess/View Servlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Aptivus/ 10003515+US+01.pdf. Accessed 24 May 2012.
12. ViiV. Highlights of prescribing information. http://www.accessdata.fda. gov/drugsatfda-docs/label/2009/021548s021,022116s005lbl.pdf. Accessed 24 May 2012.
13. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney International 2006; 69:375-82. (Pubitemid 43323090)
14. Hanratty R, Chonchol M, Miriam Dickinson L, et al. Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association-European Renal Association 2010; 25:801-7.
15. Alves TP, Hulgan T, Wu P, et al. Race, kidney disease progression, and mortality risk in HIV-infected persons. Clinical Iournal of the American Society of Nephrology : CJASN 2010; 5:2269-75.
16. Ryom L, Kamara DA, Worm SW, et al. for the D:A:D Study Group. Development of a definition for rapid progression of renal disease in HIV-positive persons. In: 13th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, Rome, Italy, 14-16 July 2011.
17. Young J, Schafer J, Fux CA, et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012; 26:567-75.
18. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. The Journal of Infectious Diseases 2008; 197:102-8. (Pubitemid 351263473)
19. Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation 2004; 44:e81-4. (Pubitemid 39445931)
20. Schmid S, Opravil M, Moddel M, et al. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Archiv : An International Journal of Pathology 2007; 450:665-70. (Pubitemid 46986233)
21. Izzedine H, M'Rad MB, Bardier A, Daudon M, Salmon D. Atazanavir crystal nephropathy. AIDS 2007; 21:2357-8.
22. Chang HR, Pella PM. Atazanavir urolithiasis. The New England Journal of Medicine 2006; 355:2158-9.
23. Hamada Y, Nishijima T, Watanabe K, et al. High Incidence of Renal Stones Among HIV-Infected Patients on Ritonavir-Boosted Atazanavir Than in Those Receiving Other Protease Inhibitor-Containing Antiretroviral Therapy. Clinical infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2012; 55:1262-9.
24. Albini L, Cesana BM, Motta D, et al. A Randomized, Pilot Trial to Evaluate Glomerular Filtration Rate by Creatinine or Cystatin C in Naive HIV-Infected Patients After Tenofovir/Emtricitabine in Combination With Atazanavir/Ritonavir or Efavirenz. J Acquir Immune Defic Syndr 2012; 59:18-30.
25. Dauchy FA, Lawson-Ayayi S, de La Faille R, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney International 2011; 80:302-9.
26. Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M. Ritonavirboosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS 2011; 25:1671-3.
27. Doco-Lecompte T, Garrec A, Thomas L, Trechot P, May T, Rabaud C. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS 2004; 18:705-6. (Pubitemid 38393477)
28. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2006; 42:283-90. (Pubitemid 43054205)
29. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavirritonavir-didanosine. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2003; 37:e174-6.
30. Lastours DV, Silva E, Daudon M, Porcher R, Sauvageon H, Molina J. Atazanavir (ATV) and darunavir (DRV) cristalluria and high ATV and DRV concentrations in urine of asymptomatic patients receiving ATV and DRV based regimens. In: 52nd ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 9-12 September 2012.
31. Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Laboratory Investigation; A Journal of Technical Methods and Pathology 2011; 91:852-8.
32. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy) propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrobial Agents and Chemotherapy 2004; 48:1469-87. (Pubitemid 38544348)
33. Lebrecht D, Venhoff AC, Kirschner J, Wiech T, Venhoff N, Walker UA. Mitochondrial tubulopathy in tenofovir disoproxil fumaratetreated rats. J Acquir Immune Defic Syndr 2009; 51:258-63.
34. Lee JC, Marosok RD. Acute tubular necrosis in a patient receiving tenofovir. AIDS 2003; 17:2543-4. (Pubitemid 38393331)
35. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2003; 36:1070-3. (Pubitemid 36513295)
36. Menezes AM, Torelly J Jr., Real L, Bay M, Poeta J, Sprinz E. Prevalence and Risk Factors Associated to Chronic Kidney Disease in HIVInfected Patients on HAART and Undetectable Viral Load in Brazil. PloS one 2011; 6:e26042.
37. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2005; 40:1194-8. (Pubitemid 40490248)
38. Overton ET, Nurutdinova D, Freeman J, Seyfried W, Mondy KE. Factors associated with renal dysfunction within an urban HIVinfected cohort in the era of highly active antiretroviral therapy. HIV Medicine 2009; 10:343-50.
39. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2010; 51:496-505.
40. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47:74-8. (Pubitemid 351619372)
41. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association-European Renal Association 2005; 20:743-6. (Pubitemid 40520651)
42. Squires K, Pozniak AL, Pierone G Jr., et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Annals of Internal Medicine 2003; 139:313-20.
43. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA : The Journal of the American Medical Association 2004; 292:191-201. (Pubitemid 38917996)
44. Wyatt CM, Klotman PE. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert Opinion on Drug Safety 2006; 5:275-87. (Pubitemid 43379625)
45. Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. Journal of Postgraduate Medicine 2006; 52:296-7. (Pubitemid 44862772)
46. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. The New England Journal of Medicine 2008; 358:568-79.
47. Crum-Cianflone N, Ganesan A, Teneza-Mora N, et al. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care and STDs 2010; 24:353-60.
48. Deti EK, Thiebaut R, Bonnet F, et al. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Medicine 2010; 11:308-17.
49. Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk factors for ESRD in HIV-Infected individuals: traditional and HIV-related factors. American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation 2011.
50. Peters L, Grint D, Lundgren JD, et al. HCV viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS in press 2012.